Novartis AG is poised to significantly expand the market and sales for Kisqali (ribociclib) with the CDK4/6 inhibitor’s new US Food and Drug Administration approval for treatment of patients with early breast cancer.
Kisqali Label Expansion Will Double Market Size Opportunity
The US FDA approved the drug with a broad label for patients with HR+/HER2- early breast cancer at high risk of recurrence, a potentially multibillion-dollar opportunity.
More from New Products
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.